2BBBullish & Bearish
Health Care

Filana Therapeutics Inc (FLNA) Stock Score & Signals

Filana Therapeutics Inc (FLNA) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 20 out of 100.

About Filana Therapeutics Inc

Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.

2BB score and signals

Filana Therapeutics Inc’s current 2BB score is 20 out of 100, built from the signal categories below.

SignalScoreReading
Activity3Very Low
Momentum50Stable
Financial strength23Weak
Quality20Weak
Risk85Very High

Company facts

HeadquartersAustin, Texas, United States
Founded1998
Employees19
52-week range$0.67 – $2.27

Recent earnings

Report dateEPS actualEPS estimateRevenue actualRevenue estimate
2026-08-05—-0.357—$0.00
2026-05-06—-0.3162—$0.00